As my title suggests, I'm going to name 10 stocks that you can buy right now in July. These stocks are all cheap given their future prospects. I own many of them in my personal holdings and am seriously considering the rest. After I fill you in on the 10 stocks, keep reading below and I'll reveal which ones I'm most bullish on at today's prices.

1 tech blue chip on sale
When a company sells for as cheap as Microsoft (Nasdaq: MSFT) is trading (single-digit price multiples after backing out cash), something tangible is usually amiss.

With Microsoft, it's less that something's wrong and more that something could go wrong. Mr. Softy has a lot going on, and we could certainly take potshots at the areas it doesn't dominate, such as Web search and smartphones. But let's remember where Microsoft's bread is buttered: Microsoft Windows and Office. There are certainly threats there, too, but again, it's trading pretty cheaply for just "could go wrong."

1 little company with a massive, hidden dividend
Back in May, I wrote about mini-conglomerate National Presto (NYSE: NPK), "the little company with a massive, hidden dividend." Because of its recent practice of paying a small regular dividend and a large special dividend, sites like Yahoo! Finance assign National Presto a 1% dividend yield. But its actual trailing yield is 8%!

National Presto's trading a bit cheaper than it was in May, so it's a good time to check the company out.

2 retailers that are bigger than Amazon
With so much press around commerce moving from bricks-and-mortar stores to the Internet, it's easy to forget that Target (NYSE: TGT) and Best Buy (NYSE: BBY) both still have significantly more sales than But while's stock is blazing new all-time highs, Target and Best Buy shares are in the discount aisle.

Of course, they can't compete with the explosive growth of Amazon. But over the past five years, Target has grown sales by almost 5% a year, Best Buy by almost 10%. Of the two, I'm more confident of Target's future growth prospects, but Best Buy has the better balance sheet and is discounted more.

4 tight-lending banks
Below are four banks (three small U.S. banks and one large Canadian bank) that show good lending practices (a bad loan percentage of 1% or below). Although three trade at lofty price-to-tangible book values, all have been able to crank out enough earnings to present P/E ratios between 11 and 13. They also pay out pretty good dividends, ranging from 2.8% to 4.5%.

There are still problems that could occur both with the loan portfolios and outside of lending activity. For example, Canadian Imperial Bank of Commerce took a hefty trading loss back in fiscal 2008. Still, at today's prices, I'd bet on this group to beat the market from here.  

Bank Name

Market Cap (in millions)

Bad loan %

Price-to-tangible-book value


Bank of Hawaii





Financial Institutions





Community Bank System





Canadian Imperial Bank of Commerce (NYSE: CM)





Source: Capital IQ, a division of Standard & Poor's.

1 back-from-the-dead company
Even with government aid, General Motors (NYSE: GM) was such a mess that it had to declare bankruptcy in 2009. Now that it's back, it's gotten a once-bitten-twice-shy reception from the investing community as shares trade below its $33 IPO price.

Some things are the still the same: GM still operates in a capital-intensive industry against a host of global competition. What's different is that GM's streamlined, both in terms of costs and product lines (goodbye Pontiac, Saturn, Oldsmobile, and Hummer). Its balance sheet is pretty strong with a net cash position and manageable pension obligations. And not only is it currently profitable, it has tax loss carryforwards that survived bankruptcy. The upshot? In the last 12 months, GM has had an effective tax rate of 3.3%.

1 generic pick
Eli Lilly
, Pfizer, Merck, and Teva Pharmaceuticals (Nasdaq: TEVA) all trade at similar forward P/E ratios in the range of 8-10. The first three are discounted because investors worry that Big Pharma's drug pipelines won't be able to replenish sales lost to expiring blockbuster patents. What's interesting about Teva is that it is primarily a generic-drug maker that benefits from patent expirations. Seems like a disparity worth exploring to me.

The stocks I'm most bullish on
Each of the 10 stocks above are worthy of your consideration. All are priced to beat the market from here. But if you forced me to pick the ones I think offer the best risk/reward today, I'd pick Teva, GM, Best Buy, Microsoft, and National Presto (in no particular order). I hope these ideas serve you well. If you're hankering for one more stock idea, check out our free report: The Only Energy Stock You'll Ever Need. Just click here to access it immediately.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.